Abstract
Objectives: The aim of our study was to compare the accuracy of contrast enhanced MRI and FDG PET-CT in the staging, treatment evaluation and follow-up of multiple myeloma. Methods: We retrospectively reviewed 210 PET-CT and 210 MRI studies of patients affected by multiple myeloma. MRI was always performed within 15 days of PET-CT. All the images have been evaluated by two expert oncologic radiologists. Results: Patient population included 81 females and 110 males (age 61.9 ± 9.9 years-old). Sixty-two patients have been evaluated at diagnosis, 58 at the end of therapies and 90 during follow-up. In 12/62 patients (19.4%) at diagnosis, differences between MRI and PET-CT findings determined changes in the staging: PET-CT was responsible for 11 down-staging (17.7%) and MRI only for one (1.6%). In 27/40 patients (67.5%) with good or complete clinical response to therapies the normalization of findings was faster for PET-CT than MRI. Ten out of 90 patients (10/90 – 11.1%) in follow-up protocol presented clinical recurrence of the disease: MRI detected active lesions in 8 of them (80.0%) and PET-CT in 5 patients (50.0%, all detected by MRI too). Conclusions: MRI achieved better results than PET-CT in the staging and in patients with multiple myeloma
More>>
Spinnato, P., E-mail: paolospinnato@email.it;
[1]
Bazzocchi, A., E-mail: abazzo@inwind.it [Imaging Division, Clinical Department of Radiological and Histocytopathological Sciences, University of Bologna, Sant’Orsola-Malpighi Hospital, Via Massarenti 9, 40138 Bologna (Italy);
Diagnostic and Interventional Radiology, “Rizzoli” Orthopaedic Institute, Via G.C. Pupilli 1, 40136 Bologna (Italy)];
Brioli, A., E-mail: abrioli@libero.it;
[2]
Nanni, C., E-mail: cristina.nanni6@unibo.it;
[1]
Zamagni, E., E-mail: e.zamagni@unibo.it;
[2]
Albisinni, U., E-mail: ugo.albisinni@ior.it;
[3]
Cavo, M., E-mail: michele.cavo@unibo.it;
[2]
others, and
- Imaging Division, Clinical Department of Radiological and Histocytopathological Sciences, University of Bologna, Sant’Orsola-Malpighi Hospital, Via Massarenti 9, 40138 Bologna (Italy)
- Emathology and Oncology Institute “Seragnoli”, Sant’Orsola-Malpighi Hospital, Via Massarenti 9, 40138 Bologna (Italy)
- Diagnostic and Interventional Radiology, “Rizzoli” Orthopaedic Institute, Via G.C. Pupilli 1, 40136 Bologna (Italy)
Citation Formats
Spinnato, P., E-mail: paolospinnato@email.it, Bazzocchi, A., E-mail: abazzo@inwind.it [Imaging Division, Clinical Department of Radiological and Histocytopathological Sciences, University of Bologna, Sant’Orsola-Malpighi Hospital, Via Massarenti 9, 40138 Bologna (Italy), Diagnostic and Interventional Radiology, “Rizzoli” Orthopaedic Institute, Via G.C. Pupilli 1, 40136 Bologna (Italy)], Brioli, A., E-mail: abrioli@libero.it, Nanni, C., E-mail: cristina.nanni6@unibo.it, Zamagni, E., E-mail: e.zamagni@unibo.it, Albisinni, U., E-mail: ugo.albisinni@ior.it, Cavo, M., E-mail: michele.cavo@unibo.it, and others, and.
Contrast enhanced MRI and {sup 18}F-FDG PET-CT in the assessment of multiple myeloma: A comparison of results in different phases of the disease.
Netherlands: N. p.,
2012.
Web.
doi:10.1016/J.EJRAD.2012.06.028.
Spinnato, P., E-mail: paolospinnato@email.it, Bazzocchi, A., E-mail: abazzo@inwind.it [Imaging Division, Clinical Department of Radiological and Histocytopathological Sciences, University of Bologna, Sant’Orsola-Malpighi Hospital, Via Massarenti 9, 40138 Bologna (Italy), Diagnostic and Interventional Radiology, “Rizzoli” Orthopaedic Institute, Via G.C. Pupilli 1, 40136 Bologna (Italy)], Brioli, A., E-mail: abrioli@libero.it, Nanni, C., E-mail: cristina.nanni6@unibo.it, Zamagni, E., E-mail: e.zamagni@unibo.it, Albisinni, U., E-mail: ugo.albisinni@ior.it, Cavo, M., E-mail: michele.cavo@unibo.it, & others, and.
Contrast enhanced MRI and {sup 18}F-FDG PET-CT in the assessment of multiple myeloma: A comparison of results in different phases of the disease.
Netherlands.
https://doi.org/10.1016/J.EJRAD.2012.06.028
Spinnato, P., E-mail: paolospinnato@email.it, Bazzocchi, A., E-mail: abazzo@inwind.it [Imaging Division, Clinical Department of Radiological and Histocytopathological Sciences, University of Bologna, Sant’Orsola-Malpighi Hospital, Via Massarenti 9, 40138 Bologna (Italy), Diagnostic and Interventional Radiology, “Rizzoli” Orthopaedic Institute, Via G.C. Pupilli 1, 40136 Bologna (Italy)], Brioli, A., E-mail: abrioli@libero.it, Nanni, C., E-mail: cristina.nanni6@unibo.it, Zamagni, E., E-mail: e.zamagni@unibo.it, Albisinni, U., E-mail: ugo.albisinni@ior.it, Cavo, M., E-mail: michele.cavo@unibo.it, and others, and.
2012.
"Contrast enhanced MRI and {sup 18}F-FDG PET-CT in the assessment of multiple myeloma: A comparison of results in different phases of the disease."
Netherlands.
https://doi.org/10.1016/J.EJRAD.2012.06.028.
@misc{etde_22263604,
title = {Contrast enhanced MRI and {sup 18}F-FDG PET-CT in the assessment of multiple myeloma: A comparison of results in different phases of the disease}
author = {Spinnato, P., E-mail: paolospinnato@email.it, Bazzocchi, A., E-mail: abazzo@inwind.it [Imaging Division, Clinical Department of Radiological and Histocytopathological Sciences, University of Bologna, Sant’Orsola-Malpighi Hospital, Via Massarenti 9, 40138 Bologna (Italy), Diagnostic and Interventional Radiology, “Rizzoli” Orthopaedic Institute, Via G.C. Pupilli 1, 40136 Bologna (Italy)], Brioli, A., E-mail: abrioli@libero.it, Nanni, C., E-mail: cristina.nanni6@unibo.it, Zamagni, E., E-mail: e.zamagni@unibo.it, Albisinni, U., E-mail: ugo.albisinni@ior.it, Cavo, M., E-mail: michele.cavo@unibo.it, and others, and}
abstractNote = {Objectives: The aim of our study was to compare the accuracy of contrast enhanced MRI and FDG PET-CT in the staging, treatment evaluation and follow-up of multiple myeloma. Methods: We retrospectively reviewed 210 PET-CT and 210 MRI studies of patients affected by multiple myeloma. MRI was always performed within 15 days of PET-CT. All the images have been evaluated by two expert oncologic radiologists. Results: Patient population included 81 females and 110 males (age 61.9 ± 9.9 years-old). Sixty-two patients have been evaluated at diagnosis, 58 at the end of therapies and 90 during follow-up. In 12/62 patients (19.4%) at diagnosis, differences between MRI and PET-CT findings determined changes in the staging: PET-CT was responsible for 11 down-staging (17.7%) and MRI only for one (1.6%). In 27/40 patients (67.5%) with good or complete clinical response to therapies the normalization of findings was faster for PET-CT than MRI. Ten out of 90 patients (10/90 – 11.1%) in follow-up protocol presented clinical recurrence of the disease: MRI detected active lesions in 8 of them (80.0%) and PET-CT in 5 patients (50.0%, all detected by MRI too). Conclusions: MRI achieved better results than PET-CT in the staging and in patients with multiple myeloma recurrence. PET-CT, showed prompt change of imaging findings, faster than MRI, in patients with positive response to therapy.}
doi = {10.1016/J.EJRAD.2012.06.028}
journal = []
issue = {12}
volume = {81}
journal type = {AC}
place = {Netherlands}
year = {2012}
month = {Dec}
}
title = {Contrast enhanced MRI and {sup 18}F-FDG PET-CT in the assessment of multiple myeloma: A comparison of results in different phases of the disease}
author = {Spinnato, P., E-mail: paolospinnato@email.it, Bazzocchi, A., E-mail: abazzo@inwind.it [Imaging Division, Clinical Department of Radiological and Histocytopathological Sciences, University of Bologna, Sant’Orsola-Malpighi Hospital, Via Massarenti 9, 40138 Bologna (Italy), Diagnostic and Interventional Radiology, “Rizzoli” Orthopaedic Institute, Via G.C. Pupilli 1, 40136 Bologna (Italy)], Brioli, A., E-mail: abrioli@libero.it, Nanni, C., E-mail: cristina.nanni6@unibo.it, Zamagni, E., E-mail: e.zamagni@unibo.it, Albisinni, U., E-mail: ugo.albisinni@ior.it, Cavo, M., E-mail: michele.cavo@unibo.it, and others, and}
abstractNote = {Objectives: The aim of our study was to compare the accuracy of contrast enhanced MRI and FDG PET-CT in the staging, treatment evaluation and follow-up of multiple myeloma. Methods: We retrospectively reviewed 210 PET-CT and 210 MRI studies of patients affected by multiple myeloma. MRI was always performed within 15 days of PET-CT. All the images have been evaluated by two expert oncologic radiologists. Results: Patient population included 81 females and 110 males (age 61.9 ± 9.9 years-old). Sixty-two patients have been evaluated at diagnosis, 58 at the end of therapies and 90 during follow-up. In 12/62 patients (19.4%) at diagnosis, differences between MRI and PET-CT findings determined changes in the staging: PET-CT was responsible for 11 down-staging (17.7%) and MRI only for one (1.6%). In 27/40 patients (67.5%) with good or complete clinical response to therapies the normalization of findings was faster for PET-CT than MRI. Ten out of 90 patients (10/90 – 11.1%) in follow-up protocol presented clinical recurrence of the disease: MRI detected active lesions in 8 of them (80.0%) and PET-CT in 5 patients (50.0%, all detected by MRI too). Conclusions: MRI achieved better results than PET-CT in the staging and in patients with multiple myeloma recurrence. PET-CT, showed prompt change of imaging findings, faster than MRI, in patients with positive response to therapy.}
doi = {10.1016/J.EJRAD.2012.06.028}
journal = []
issue = {12}
volume = {81}
journal type = {AC}
place = {Netherlands}
year = {2012}
month = {Dec}
}